Teva's AUSTEDO XR Receives FDA Approval For Movement Disorders Treatment
18/2 06:18
(RTTNews) - The U.S. Food and Drug Administration has approved AUSTEDO XR (deutetrabenazine) extended-release tablets, a new once-daily formulation indicated in adults for tardive dyskinesia and chorea associated with Huntington's disease, Teva Pharmaceutical Industries Ltd. (TEV...